New pain drug could cut opioid use after pancreatic surgery
NCT ID NCT07423650
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a continuous infusion of nefopam, a non-opioid painkiller, can reduce opioid use and pain after pancreatoduodenectomy (a major pancreatic surgery). About 93 adults will be randomly assigned to receive nefopam, lidocaine, or standard epidural pain relief. Researchers will measure opioid consumption and pain scores over 48 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nefopam
What this could lead to
If it works, this could offer a better way to manage pain after pancreatic surgery, reducing the need for opioids and their side effects.
What could go wrong
This is a small, early-phase trial focused on pain control, not a cure. The results may not apply to other surgeries or patients, and nefopam may not prove superior to existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prof. O. Fodor Regional Institute of Gastroenterology and Hepatology
RECRUITINGCluj-Napoca, Cluj, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••